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ABSTRACT 
Spasticity or increase in muscle tone is one of the problems following stroke. Due to this increase in 
muscle tone, patients are confronted to problems in motor control and difficulties in activities of daily living 
and complications such as shortness and contracture. The aim of this study is to compare the effects of 
using splint or botulinum toxin injection on spasticity, range of motion and upper extremity function in a 3-
month period. The method of this research study was a two comparison design, done in rehabilitation 
clinics in Tehran. At first, 50 patients with chronic stroke were selected and based on the inclusion 
criteria, a total of 28 stroke patients after completing the consent forms were entered to intervention 
groups of splint or botulinum toxin injection and they were followed up about 3 months. At last, 18 patients 
completed the study. Goniometery was the method to measure range of motion, and Modified Ashworth 
scale was used to examine the spasticity and the upper extremity function was scored based on Fugl-
Meyer assessment. All outcome measures improved in each group, but the differences between two 
groups were not significant (p value > 0.05). In this study, the effects of botulinum toxin injection and 
Volar-Dorsal Wrist/Hand Immobilization splint were not significantly different between the interventions in 
a 3-month follow-up. 
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Stroke is known as the third cause of death. 
Incidence rate of stroke in Iran is nearly two times 
higher than that in Europe and the average age of the 
disease is about 10 years Lower [ 1]. One of the 
complications after cerebrovascular accident is 
spasticity or muscle hypertonicity that is determined 
with increase in speed-dependent resistance against 
passive tension and the intensive stretch reflexes. After 
stroke, due to the rise of muscle tone, increased reflex 
activity and reduced inhibitory control patients are 
confronted to problems in motor control and these 
problems also lead to difficulties in activities of daily 
living and complications such as shortness and 
contracture [ 2]. The most recovery of neuromuscular 
system may occur within the 6 months after the 
accident. Long term recovery period of these systems 
may be associated with problems such as spasticity, 
Rigidity and defects in motor functions such as 
synkinesis (involuntary movements in other parts, while 
moving another extremity). Neurolysis, denervation 
with chemicals and casting techniques are considered as 
treatment methods to resolve these complications [ 2,  3]. 
Alongside current spasticity preventions such as stretch, 
exercise and positioning, treatment options include oral 
anti-spasm drugs, blocking by phenol, baclofen and 
botulinum toxin local injections [ 4]. Oral antispasmodic 
medications often have limited and short-term effects 
and lead to complications such as weakness, dizziness 
and dry mouth [ 5,  6]. Neurolysis by injecting phenol or 
alcohol effectively reduces spasticity [ 7,  8], but is 
followed by severe pain. Invasive method of intrathecal 
baclofen injection leads to severe reactions such as 
nausea, vomiting and headache [ 9,  10]. Botulinum 
Toxin (Botox or Dysport) as a degenerative chemical 
drug with reversible clinical effects is another way to 
reduce muscle spasticity in stroke patients. Botulinum 
toxin causes a neuromauscular block in acetylcholine 
release, thereby preventing neuromuscular transmission 
and muscle contraction and many studies have reported 
the effects of this drug on spasticity [ 11- 15]. There are 
lots of controversies in this regard. Hesse, Bhakta and 
their colleagues studied the impact of botulinum toxin  
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Table 1. Characteristics of the 2 study groups 
Variable Botox (n=9) Splint (n=9) 
Age (years) 48.77 ± 10.43 52 ± 10.41 
Sex (women/men) 7/2 4/5 
Time since stroke (months) 34.11 ± 31.07 29.22 ± 13.90 
Mean MMSE 25.88 ± 4.28 27.44 ± 2.69 
Mean MAS 2.88 ± 1.26 2.77 ± 1.20 
FMA 23.22 ± 13.47 23.22 ± 12.93 
Values are mean ± SD of each variable. 
MMSE: Mini Mental Status Exam. 
MAS: Modified Ashworth scale. 
FMA: Focal Muscular Atrophies 
on spasticity and concluded that the injection of 
botulinum toxin is a safe and effective method for 
reducing disability in spastic patients [ 16,  17]. Splints 
are therapeutic devices which prevent contracture and 
spasm progression. It has been reported that any bad 
application of splint can cause deformity and may 
worsen the spasm [ 18,  19]. Therefore, the proper use 
and wearing of splint by the patients should be checked 
by a therapist. Two groups of orthoses for the treatment 
of spasticity are: 
PATIENTS AND METHODS 
1- progressive orthoses: that is applied to improve 
the range of motion in affected joints by increasing the 
amount of slow stretch created in the joint. This 
orthoses can be used to modify or prevent spasm, 
particularly if the spasm remains after injection of 
botulinum toxin. 
2- Serial orthoses: work as progressive orthoses but 
the difference is they are prescribed as a brace, which 
gradually increase the range of motion. 
This study was designed in two groups in 
rehabilitation clinics throughout Tehran. Fifty patients 
with chronic stroke were selected by a non-randomized 
simple method and according to the inclusion criteria, a 
total of 28 stroke patients after completing the consent 
forms entered to the study and were put in splint or 
botulinum toxin injection group. Of these, 18 patients 
completed the study. Twenty patients participated till 
the end of the first month and nine patients were missed 
due to discordance and absence in the assessment 
sessions. One patient died from a second stroke just 
before the final assessment. Inclusion criteria for the 
study were: at least one year after the stroke, age 
between 20 to 64, score above 22 on the cognitive test 
of Mini Mental Status Exam (MMSE), no other 
neurological diseases, having a maximum spasticity 
score of 3 on the Modified Ashworth scale (MAS), the 
ability to sit at least 10 minutes independently on the 
edge of the bed and not receiving botulinum toxin or 
similar splints while entering the study. If any of the 
patients had the following situations, he/she would be 
excluded from the research: occurrence of orthopedic 
lesions in the upper extremity, occurrence of any other 
neurological disease, or absence in post-test evaluation. 
In this study, we used a type called volar-dorsal 
static (immobilization) splint that works through 
application of serial static force [ 3]. Because of the 
specific structure of this splint, the patient is able to 
touch objects on the palm, and this is considered as an 
advantage over other splints. Since the use of splint and 
injections of botulinum toxin have their particular costs 
for many families, thus efficiency and comparison of 
these interventions are important to resolve patient`s 
problems. Hill explained that the method of extremity 
casting was more effective than conventional methods 
such as passive range of motion exercises and static 
stretching and splinting [ 20]. But another study by 
Cusick, Novak and Lannin in 2007 has been reported 
different results such as weakness due to immobilization 
condition in the casting method [ 21]. Most of the studies 
didn’t show accurate effects of splints in reducing 
spasticity because of methodological limitations such as 
lack of inappropriate assessment and lack of control 
groups. Lai and colleagues in 2009 studied the effects of 
botulinum toxin injection accompanied by occupational 
therapy, and also examined the use of a dynamic splint 
along with those two interventions and reported 
contracture reduction and range of motion improvement 
[ 22]. In this study, through monthly clinical evaluations, 
the efficacy of botulinum toxin drug and splinting were 
examined in chronic stroke patients. 
To make the desired splint, initially positive patterns 
were made in two sizes of men and women for the left 
or right hand. Then, all splints were fabricated based on 
the patterns. Splints immobilized the wrist in 10 degrees 
of extension, thumb in hyper-abduction and fingers in 
zero, so the angles of splint were the same for all 
patients. Before the initiation of the interventions 
[splinting or botulinum toxin injection], active and 
passive range of motion of elbow, wrist and 
metacarpophalengeal joints were assessed. Other 
outcome measures were elbow and wrist spasticity and 
upper extremity function. Goniometery was the method 
to measure range of motion, and Modified Ashworth 
scale was used to examine the spasticity and the upper 
extremity function was scored based on Fugl-Meyer 
assessment. The complete initial data were gathered and 
recorded. 
Afterwards, the patients recieved botulinum toxin 
injections or splints for 3 months. In this work, volar-
dorsal wrist/hand immobilization splint and botulinum 
toxin drug type A was surveyed. Dosage for each 
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Table 2. Between-group differences in change scores for spasticity and active/passive range of motion and function 
Baseline to 1st Month 1st to 3rd Month 
Parameter 
Botox Group Splint Group Mean Difference (p value)* Botox Group Splint Group 
Mean Difference 
(p value)* 
Elbow MAS 0.22 0.33 -0.11 (0.72) 0.25 0.44 
-0.19 
(0.65) 
Wrist MAS 1.11 0.22 0.88 (0.04) -0.62 0.22 
-0.84 
(0.04) 
Elbow AROM -10.88 -5.00 -5.88 (0.65) -27.75 7.77 
-35.52 
(0.07) 
Elbow PROM 0.00 -1.66 1.66 (0.42) 0.00 0.00 
0.00 
(1) 
Wrist AROM -4.00 -3.66 -0.33 (0.97) -5.87 -2.33 
-3.54 
(0.73) 
Wrist PROM -7.77 -10.00 2.22 (0.86) -16.87 -7.22 
-9.65 
(0.45) 
MP AROM 17.00 -4.77 21.77 (0.18) -7.50 -2.44 
-5.05 
(0.34) 
MP PROM -1.66 -2.22 0.55 (0.88) 0.00 -1.11 
1.11 
(0.73) 
FMA -2.66 -2.11 -0.55 (0.73) -8.25 -2.55 
-5.69 
(0.23) 
*independent sample t test. 
muscle was 50-150 IV based on the bulk of muscles 
(FCR, FCU, Pronator Teres, FDP, FDS, FPL, Palmaris 
Longus). Patients in the splint group were clarified to 
wear these splints 2 hours a day and all the night (6 to 8 
hours) about 3 months. Re-evaluation at the end of each 
month for both groups was performed. At the end of the 
first month, 20 patients (11 in splint group and 9 in 
botulinum toxin group) and finally at the end of the 
third month, 17 patients (9 in splint group and 8 in 
botulinum toxin group) were present for the assessment. 
In this 3-month period, the patients were called and 
reminded to use the splint. It should be noted that all 
patients were also participating in a routine occupational 
therapy program three times a week during the study. 
We calculated the descriptive and analytic statistics 
using the software SPSS, version 17. To investigate 
whether one of the groups changed more than the other 
group at the end of 1st month and at the end of 3rd 
month, we calculated change scores for each group and 
compared them by using an independent sample t test. 
We also used analyses of variance (ANOVAs) with 
repeated measures with a between-subject factor at 2 
levels(2 groups) and a within-subject factor at 3 levels 
(time: baseline,1st month, 3rd month).The interaction of 
group and time served to determine the efficacy of the 
each therapy on the outcome measures. Significance 
was set at p < 0.05. 
RESULTS 
Table 2 shows the between-group comparisons of 
the change scores for upper limb motor function, elbow 
and wrist spasticity level, active/passive range of motion 
of elbow, wrist and metacarpophalengeal joints from the 
beginning to the end of first month and between the 
ends of 1st to end of 3rd month. 
Table 3 presents the motor recovery, spasticity and 
range of motion of patients at baseline, end of first and 
at the end of third month. According to the results 
contained in Table 3, all variables in both groups have 
been improved to some extent but the difference 
between two groups was not significant in any outcome. 
DISCUSSION 
Results of this study show that using volar-dorsal 
wrist/hand immobilization splint or botulinum toxin 
injection accompanied with routine occupational 
therapy program improves most of the outcomes, but 
the difference between two groups was not significant in 
3 months. A reason for this lack of significance can be 
the low sample size. To get better results, more cases 
would be needed. In addition, low reliability and low 
sensitivity of MAS test to show the changes could be of 
another limitation [ 23]. This test in addition to spasticity 
assessment, also evaluates thixotropy and fixed muscle 
contracture, thus using MAS as an ideal spasticity 
examination would be controversial. It seems 
electrophysiological assessments like Mmax/Hmax tests 
be good criterion for measuring spasticity. A study in 
2005 by Pizzi and colleagues have showed that using a 
volar splint about 3 months reduced spasticity and this 
improvement was only seen with neurophysiological 
tests and the MAS results were not significant [ 24]. The 
data in Table 2 shows that either during the first month 
or during the second and the third months, the impact on 
wrist spasticity was significantly different between 
groups. Spasticity of the wrist was significantly reduced  
Mean age of the patients was 48.77 in drug injection 
group and 52.55 in the splint group. The average time 
passed since stroke was 34.11 months in the botulinum 
toxin injection group and 29.22 in the splint group. 
Mean cognitive scores (MMSE) was 25.88 in injection 
group and 27.44 in the splint group. In addition, the 
patients were in a similar status according to spasticity 
level and function scores (Table 1). 
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during the first month in botulinum toxin injection 
group, although this improvement didn’t remain in the 
next 2 months and the intensity of spasticity increased 
again while in the splint group, the spasticity improved 
at the same period. Thus, it is presented that trend of 
spasticity reduction in splint group has been consistent 
during three months of study but botulinum toxin 
injection trend has been a different process so that at 
first there was a period of a great reduction in the 
severity of spasticity and after the first month this 
outcome gradually increased again. This could indicate 
that effect of botulinum toxin injection on spasticity is 
short-term and temporary. So, according to the 
ascending improvement of spasticity in the splint group 
and the unstable trend of spasticity improvement in the 
group of botulinum toxin injections, it can be said that 
perhaps the time (3 months) was not enough to get more 
definite results comparing the interventions impacts. We 
hope that future research will pursue this issue. 
Table 3. Motor Recovery, Spasticity, and Passive/Active Range of motion scores of patients at baseline, 1st Month, and 3rd Month 
Parameter Group Pretreatment 1st month 3rd month Δ (95% CI) p value* 
Botox 1.88 ± 0.92 1.66 ± 0.86 1.50 ± 0.53 0.50 (-0.34-1.34) Elbow MAS Splint 1.55 ± 0.72 1.22 ± 0.83 0.77 ± 0.44 0.77 (0.49-1.05) 0.525 
Botox 2.88 ± 1.26 1.77 ± 1.09 2.62 ± 0.51 0.50 (-0.34-1.34 Wrist MAS Splint 2.77 ± 1.20 2.55 ± 1.42 2.33 ± 1.41 0.44 (-0.14-1.02) 0.914 
Botox 53.00 ± 48.53 63.88 ± 45.39 82.75 ± 39.61 -38.12 (-65.20- -11.04 Elbow AROM 0.39 Splint 84.44 ±40.03 89.44 ± 35.03 81.66 ± 40.85 2.77 (-9.43-26.97) 
Botox 135.00 ± 2.50 135.00 ± 0.00 135.00 ± 0.00 0.00 (-1.88-1.88) Elbow PROM 0.455 Splint 133.88 ± 5.46 135.55 ± 1.66 135.55 ± 1.66 -1.66 (-5.38-2.06) 
Botox 18.55 ± 18.97 22.55 ± 26.29 26.87 ± 28.27 -9.75 (-21.83-2.33) Wrist AROM 0.618 Splint 7.22 ± 7.12 10.88 ± 9.98 13.22 ± 11.27 -6.00 (-14.78-2.78) 
Botox 156.66 ± 21.21 164.44 ± 25.30 181.87 ± 13.34 -25.00 (-44.26- -5.74) Wrist PROM 0.557 Splint 137.77 ± 27.16 147.77 ± 26.35 155.00 ± 19.03 -17.22 (-34.62-0.18) 
Botox 24.44 ± 46.59 7.44 ± 10.00 14.62 ± 14.82 -5.25 (-11.65-1.15) MP AROM 0.619 Splint 2.44 ± 6.61 7.22 ± 8.70 9.66 ± 9.00 -7.22 (-11.82- -2.62) 
Botox 95.00 ± 5.00 96.66 ± 7.07 96.77 ± 3.72 -1.87 (-5.09-1.35) MP PROM 0.724 Splint 91.66 ± 10.00 83.88 ± 8.20 95.00 ± 5.59 -3.33 (-10.39-3.73) 
Botox 23.22 ± 13.47 25.88 ± 14.40 32.00 ± 18.66 -10.37 (-18.51- -2.23) FMA 0.247 Splint 23.22±12.93 25.33 ± 11.56 27.88 ± 13.56 -4.66 (-9.24-4.11) 
Values are mean ± SD. 
Abbreviations: CI, confidence interval; Δ, mean change at 3rd Month from baseline. 
*ANOVA for repeated measures. 
 
Kirazli and colleagues in 1998 concluded that 
injecting botulinum toxin in spastic soleus muscles has 
significant reduction in the muscle’s spasticity in the 
second and fourth weeks, but this decrease was not seen 
at the end of weeks 8 and 12 [ 25]. In another study by 
Eduardo, the results were different from our study and 
spasticity continued to diminish even up to 32 weeks 
after injection of the botulinum toxin and these changes  
were significant [ 26]. Changes in active and passive 
wrist ROM showed a similar recovery in both groups 
but the change differences between two groups were not 
significant, perhaps due to low number of patients. In 
Wallen`s study among 4 groups of cerebral palsy 
children [botulinum toxin injection, botulinum toxin 
injection along with occupational therapy, occupational 
therapy, and control] similar effects on upper extremity 
were reported [ 27], but in contrast to our work, Eduardo 
reported that range of motion may improve up to 32 
weeks after injection of the botulinum toxin. The 
advantages of that research seems to be evaluation of 
isolated muscles and adjusting injection doses based on 
the need of each muscle [ 26]. Active ROM of 
metacarpophalengeal joints had little changes in both 
groups but the differences compared between two 
groups were not evident. Although trend of this changes 
was gradually and continuously improving in patients 
who used the splint, but injection of botulinum toxin in 
the first month clearly decreased active range of motion 
that can be caused by temporary poisoning and 
weakening effect of this drug on muscles. This active 
ROM reduction was modulated perhaps due to the time 
went by the end of third month. Changes in passive joint 
range of motion of metacarpophalengeal joints were not 
evident either within or between groups, and these 
results were predictable due to complete passive range 
of motion in most patients at the baseline. Upper 
extremity function as well as other variables didn't show 
significant difference between interventions at the end 
of treatment, although the improvement process within 
each group gradually increased, and recovery changes 
of both interventions in the first month were nearly the 
same but in the botulinum toxin injection group 
continued to increase more quickly. The slow trend of 
recovery in the injection group could be as a result of 
early effects of botulinum toxin that weakens the 
muscle. Obviously, the function of upper limb is 
associated with range of motion and muscle tone, 
therefore a lack of significant results in the tone and 
range of motion, can be an explanation to not having 
significant functional improvements. Research in 2000 
by Gracise and colleagues has shown that upper limb  
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function will improve in certain tasks. Gracise explains 
this improvement with regard to better perception of the 
senses and reduced spasticity and increased range of 
motion in some joints of the affected hemiplegic side as 
an outcome of using of a Garment [ 18]. Katz and 
colleagues in a study showed a strong correlation 
between spasticity and hand function [ 28]. Although the 
scales such as the MAS give little clinical information, 
and have low validity and low sensitivity to changes but 
they are still being used in many researches [ 23]. In a 
case report by Shun-fen sun, it was concluded that 
botulinum toxin injection accompanied with any other 
treatment such as CIMT, improves spasticity of upper 
limb [ 29]. So if splinting and botulinum toxin are given 
simultaneously, we may get better results. Though a 
higher sample size, further time of intervention or 
follow-up and using neurophysiological assessment 
tools alongside other clinical tests is recommended. 
In conclusion, the effects of botlunium toxin 
injection and volar-dorsal wrist/hand immobilization 
splint were not significantly different between groups in 
a 3-month follow-up. Botulinum toxin injection greatly 
reduced spasticity in short term but after a period, the 
spasticity appeared again. Botulinum toxin injections 
accompanied by occupational therapy seems to act 
beneficially like other usual treatments, although the 
possible advantages over other methods should be re-
examined. 
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